Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1XDTV | ISIN: NL0010696654 | Ticker-Symbol: UQ1
Tradegate
21.11.24
12:35 Uhr
5,340 Euro
-0,064
-1,18 %
1-Jahres-Chart
UNIQURE NV Chart 1 Jahr
5-Tage-Chart
UNIQURE NV 5-Tage-Chart
RealtimeGeldBriefZeit
5,3705,44417:06
5,3705,44017:06

Aktuelle News zur UNIQURE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14:00uniQure N.V. - 8-K, Current Report-
UNIQURE Aktie jetzt für 0€ handeln
13:10uniQure Inc.: uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy139LEXINGTON, Mass. and AMSTERDAM, Nov. 21, 2024N.V.). "The dosing of the first patient in our Phase I/II trial in temporal lobe epilepsy represents an important milestone for uniQure and our third...
► Artikel lesen
05.11.uniQure N.V. - 10-Q, Quarterly Report2
05.11.uniQure GAAP EPS of -$0.91 beats by $0.03, revenue of $2.29M misses by $4.77M3
05.11.uniQure Inc.: uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress211~ Type B meeting scheduled with the FDA in the fourth quarter of 2024 to initiate discussions regarding a potential expedited clinical development pathway for AMT-130 in Huntington's disease ~ ~...
► Artikel lesen
05.11.uniQure N.V. - 8-K, Current Report-
15.10.uniQure N.V. - 8-K, Current Report7
15.10.uniQure Inc.: uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS331LEXINGTON, Mass. and AMSTERDAM, Oct. 15, 2024N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first...
► Artikel lesen
10.10.uniQure shares coverage resumed on robust clinical portfolio15
23.09.uniQure N.V. - 8-K, Current Report4
23.09.FDA grants Orphan Drug status to uniQure's Fabry therapy6
23.09.uniQure Inc.: uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease293LEXINGTON, Mass. and AMSTERDAM, Sept. 23, 2024N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the...
► Artikel lesen
20.08.uniQure retains PT with Buy rating on gene therapy prospects16
15.08.uniQure N.V. - 8-K, Current Report1
15.08.uniQure Inc.: uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease442LEXINGTON, Mass. and AMSTERDAM, Aug. 15, 2024N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first...
► Artikel lesen
05.08.uniQure wields axe again as Huntington's therapy progresses5
02.08.UniQure to cut 65% of workforce, or 300 jobs, in major restructuring3
01.08.UniQure restructuring to claim 300 jobs4
01.08.UniQure, Arbutus and HilleVax all lay off staff as biotechs streamline operations and cut costs4
01.08.uniQure N.V. - S-8, Securities to be offered to employees in employee benefit plans3
Seite:  Weiter >>
55 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1